ClinicalTrials.gg
CompletedNCT02988869Updated Jun 16, 2020

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

A Phase 4 interventional study of Tiotropium/Formoterol and Tiotropium in COPD, sponsored by Neutec Ar-Ge San ve Tic A.Ş. Completed at 1 site in Turkey. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Neutec Ar-Ge San ve Tic A.Ş · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tiotropium · Pulmonary Disease, Chronic Obstructive.

Enrollment
64th of 105
84 · median 131
Started
2016
with 3 others
Phase 4
52 of 105
none open now
Registered
87th of 105
by date
Lead sponsor
2 of 105
Neutec Ar-Ge San ve Tic A.Ş

Among the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive, this one is the 64th largest by enrollment, is one of 4 that started in 2016, is one of 52 in phase 4, and was the 87th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tiotropium

tiotropium: first FDA approval 2004 (SPIRIVA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The overall objective is to asses the bronchodilator effect of once daily Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.) monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler + formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable moderate to severe COPD.

Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1 hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min [10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].

Read the detailed description

The overall objective is to asses the bronchodilator effect of once daily Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.) monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler + formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable moderate to severe COPD.

Patients will be randomly assigned to receive Tiotropium/Formoterol combination as dry powder for inhalation by Discair® (test inhaler, n = 29) or Tiotropium as dry powder capsule for inhalation by HandiHaler or tiotropium dry powder capsule for inhalation by HandiHaler + formoterol as dry powder capsule for inhalation by Aerolizer. Patients will be evaluated at 4 consecutive visits: baseline (enrollment), screening, treatment, and 24h after treatment.

For newly diagnosed and formerly diagnosed patients who are not on COPD medication, the screening visit will be performed on the day of enrollment. For formerly diagnosed patients receiving COPD treatment, the day of the screening visit will be based on the completion of a run-in period, with the length determined by the specific medication. During the run-in period, salbutamol (100 µg inhaler) will be prescribed as a rescue medication.

Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1 hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min [10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Tiotropium
  • Formoterol
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥40 years with diagnosis according to the current GOLD (The Global Initiative for Chronic Obstructive Lung Disease) strategy.
  • Patients who have symptomatic stable moderate to severe COPD diagnosis with post-bronchodilator /FVC ratio \<0.70, and FEV1 \<80% of predicted normal at screening visit.
  • Current smokers or ex-smokers with a smoking history of at least 10 pack-years
  • Patients who have no exacerbation within last 4 weeks
  • Female patients with using effective method
  • Patients who signed written prior to participation
  • Patients who accept to comply with the requirements of the protocol
  • Patients who have a capability of communicate with investigator

Exclusion criteria

Exclusion Criteria:

  • History of to drugs contains anticholinergics, beta-adrenergic, lactose
  • Diagnosis of asthma
  • Patients vaccinated with within 2 weeks prior to screening visit or during run-in period.
  • Patients who had exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral treatment within 4 weeks prior to screening visit or during run-in period.
  • Patients who have a history of myocardial infarction, hearth failure, acute ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks
  • Patients who have lung cancer
  • Patients with active tuberculosis
  • Patients who use oxygen therapy
  • Patients who have common interstitial lung diseases like cystic fibrosis, bronchiolitis obliterans
  • Patients with serious liver or renal disease that leads to organ failure
  • Women who are pregnant or nursing
  • History of allergic rhinitis and atopy
  • Known symptomatic prostatic hypertrophy requiring drug therapy or operation
  • Patients with narrow-angle glaucoma requiring drug therapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Tiotropium/Formoterol

    Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®

    Drug: Tiotropium/Formoterol

  • Active comparator
    Tiotropium

    Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler

    Drug: Tiotropium

  • Active comparator
    Tiotropium + Formoterol

    Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer

    Drug: Formoterol · Drug: Tiotropium

Interventions

  • DrugTiotropium/Formoterol

    Drug pages: Tiotropium · Formoterol

    Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®

    Also known as: TRITON 18/12 mcg Discair Inhalation Powder

  • Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler

    Also known as: SPIRIVA 18 mcg Inhalation Powder

  • Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer

    Also known as: FORADIL 12 mcg Inhalation Powder

  • Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler

    Also known as: SPIRIVA Inhalation Powder

06

What researchers measure

Primary outcomes

  1. Mean max change (ml) from baseline in FEV1 over a period of 24 h.

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  2. Mean % change from baseline in FEV1 over a period of 24 h.

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  3. Mean max change (ml) from baseline in FVC over a period of 24 h.

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  4. Mean % change from baseline in FVC over a period of 24 h.

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  5. FEV1 (AUC0-12) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 12 hours post-treatment (Day 1)

  6. FVC (AUC0-12) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 12 hours post-treatment (Day 1)

  7. FEV1 (AUC0-24) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)

  8. FVC (AUC0-24) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)

  9. FEV1 (AUC12-24) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)

  10. FVC (AUC12-24) response

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)

Secondary outcomes

  1. The time to onset of bronchodilator effect

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  2. The time to onset of maximum effect

    Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.

    Time frame: Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)

  3. Evaluation of safety (Physical examination, numbers of adverse reactions and abnormal laboratory values related to treatment)

    Time frame: Predose and up to 24 hours postdose

07

Study locations

1 site
  • Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
    Istanbul, 34020, Turkey
08

References and documents

Publications

  • Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 microg once daily via a Discair inhaler), tiotropium alone (18 microg by Handihaler) or combined with formoterol (12 microg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019 Dec;35(12):2187-2196. doi: 10.1080/03007995.2019.1654722. Epub 2019 Sep 16. PubMed 31397184 ↗
  • Yildiz BP, Bayraktaroglu M, Gunen H. Reply: Re: Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 mug once daily via a discair inhaler), tiotropium alone (18 mug by handihaler) or combined with formoterol (12 mug twice daily by aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019;35(12):2187-2196. Curr Med Res Opin. 2020 Jun;36(6):1061-1062. doi: 10.1080/03007995.2020.1754187. Epub 2020 Apr 29. No abstract available. PubMed 32270722 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Aug 2017, 12 months.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2016
First posted
Dec 9, 2016
StartActual
Aug 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02988869
Lead sponsor
Neutec Ar-Ge San ve Tic A.Ş
Responsible party
Sponsor
First posted
Dec 9, 2016
Start date
Aug 2016
Primary completion
Aug 2017
Completion
Aug 2017
Last update
Jun 16, 2020

Study contacts

Pinar Yildiz, Professor Doctor
principal investigator · Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital-Turkey

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tiotropium · Formoterol

Start the discussion